People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Business Services, Other Technology, Other, Biotechnology, Investment Vehicle
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Media6Degrees Inc | — | Business Services | Series B | $57.5M | $552.4M | 2009 |
| Banyan Infrastructure Corp | — | Other Technology | Series B | $29.0M | $309.0M | 2022 |
| trialmatch.me, Inc. | — | Other Technology | Series B | $27.7M | $349.2M | 2021 |
| Timesight Systems Inc | — | Other Technology | Seed | $7.4M | $3.9M | 2012 |
| Jade Harvest, LLC | — | Other | Pre-Seed | $780K | $18.0M | 2017 |
| Gemina Laboratories Ltd. | — | Biotechnology | Pre-Seed | $673K | $1.7M | 2022 |
| Cannavations Investors, LLC. | — | Other | Pre-Seed | $525K | $12.1M | 2017 |
| GF Fund I, LLC | — | Investment Vehicle | Pre-Seed | $225K | $5.2M | 2018 |
| FGM Investors, LLC. | — | Other | Pre-Seed | $125K | $2.9M | 2017 |
ROBERT GREENE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT GREENE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Christopher Fox | 4 | 4 |
| William Zachary Greene | 3 | 3 |
| David Bell | 1 | 17 |
| ALAN MURRAY | 1 | 12 |
| Ted Maidenberg | 1 | 9 |
| Scott Barclay | 1 | 8 |
| Mark Siegel | 1 | 8 |
| David Pakman | 1 | 6 |
| William Greene | 1 | 6 |
| Scott Carter | 1 | 6 |
| JOSHUA ABRAM | 1 | 5 |
| MICHAEL LIGGETT | 1 | 5 |
| Paul Matteucci | 1 | 5 |
| Kathy Leake | 1 | 4 |
| Robert Rosenberg | 1 | 4 |
| Thomas Uhlman | 1 | 4 |
| Michael DiPiano | 1 | 4 |
| Daniel Ruch | 1 | 4 |
| Kareem Dabbagh | 1 | 4 |
| Martin Cronin | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.